СИНДРОМ ГИПОТИРЕОЗА: РОЛЬ ТРИЙОДТИРОНИНА В ДИАГНОСТИКЕ И КОМБИНИРОВАННОЙ ТЕРАПИИ (ОБЗОР ЛИТЕРАТУРЫ)

Аннотация

Синдром гипотиреоза является одной из самых часто встречающихся патологий эндокринной системы. Оценка эутиреоидного статуса далеко не всегда может быть проведена по показателю ТТГ. У ряда пациентов с нормальными уровнями ТТГ и клинической картиной гипотиреоза концентрация T₃ в сыворотке крови определяется на нижней границе нормы или ниже неё при высоком содержании свободного Т₄ в крови. В мировой практике накоплен положительный опыт совместного применения препаратов левотироксина натрия и лиотиронина – синтетической формы экзогенного трийодтиронина. В ряде исследований отмечаются преимущества применения комбинированной терапии гипотиреоза над монотерапией левотироксином у определённых групп пациентов. Описаны возможные причины неэффективности стандартного лечения гипотиреоза.

Об авторах

Список литературы

Asvold B.O., Vatten L.J., Bjoro T. Changes in the prevalence of hypothyroidism: the HUNT Study in Norway. Eur. J. Endocrinol. 2013; 169: 613-20.

Garmendia Madariaga A., Santos Palacios S., Guillen-Grima F., Galofre J.C. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J. Clin. Endocrinol. Metab. 2014; 99: 923-31.

Knudsen N., Bulow I., Jorgensen T., Lauberg P., Ovesen L., Perrild H. Comparative study of thyroid function and types of thyroid dysfunction in two areas in Denmark with slightly different iodine status. Eur. J. Endocrinol. 2000; 143: 485–91.

Abdalla S.M., Bianco A.C. Defending plasma T3 is a biological priority. Clin. Endocrinol. 2014; 81: 633–41.

Chaker L., Bianco A.C., Jonklaas J., Peeters R.P. Hypothyroidism. Lancet. 2017; 390: 1550–62.

Andersen S., Pedersen K.M., Bruun N.H., Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J. Clin. Endocrinol. Metabol. 2002; 87: 1068–72.

Elmor R., Sandulli W., Carter C.A. The economic impact of changing levothyroxine formulations in difficult-to-treat hypothyroid patients: an evidence-based model. Pharmacoeconomics. 2017; 2: 1–10.

Hennessey J.V. The emergence of levothyroxine as a treatment for hypothyroidism. Endocrine. 2017; 55: 6–18.

Kraut E., Farahani P. A systematic review of clinical practice guidelines’ recommendations on levothyroxine therapy alone versus combination therapy (LT4 plus LT3) for hypothyroidism. Clin. Invest. Med. 2015; 38: E305–13.

Perros P. European Thyroid Association guidelines on L-T4+L-T3 combination for hypothyroidism: a weary step in the right direction. Eur. Thyroid J. 2012; 1: 51–4.

Wiersinga W.M., Duntas L., Fadeyev V., Nygaard B., Vanderpump M.P. 2012 ETA guidelines: the use of L-T4 + L-T3 in the treatment of hypothyroidism. Eur. Thyroid J. 2012; 1: 55–71.

Dew R., Okosieme O., Dayan C., Eligar V., Khan I., Razvi S. et al. Clinical, behavioural and pharmacogenomic factors influencing the response to levothyroxine therapy in patients with primary hypothyroidism-protocol for a systematic review. Syst. Rev. 2017; 6: 60-71.

Saravanan P., Chau W.F., Roberts N., Vedhara K., Greenwood R., Dayan C.M. Psychological well-being in patients on ‘adequate’ doses of L-thyroxine: results of a large, controlled community-based questionnaire study. Clin. Endocrinol. 2002; 57: 577–85.

Wekking E.M., Appelhof B.C., Fliers E., Schene A.H., Huyser T., Tijssen J.G.P. et al. Cognitive functioning and well-being in euthyroid patients on thyroxine replacement therapy for primary hypothyroidism. Eur. J. Endocrinol. 2005; 153: 747–53.

Panicker V., Evans J., Bjoro T., Asvold B.O., Dayan C.M., Bjerkeset O. A paradoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. Clin. Endocrinol. 2009; 71: 574–80.

Peterson S.J., Cappola A.R., Castro M.R., Dayan C.M., Farwell A.P., Hennessey J.V. et al. An online survey of hypothyroid patients demonstrates prominent dissatisfaction. Thyroid. 2018; 28: 707–21.

Peterson S.J., McAninch E.A., Bianco A.C. Is a normal TSH synonymous with “euthyroidism” in levothyroxine monotherapy? J. Clin. Endocrinol. Metab. 2016; 101: 4694–973.

Gereben B., McAninch E.A., Ribeiro M.O., Bianco A.C. Scope and limitations of iodothyronine deiodinases in hypothyroidism. Nat. Rev. Endocrinol. 2015; 11: 642–52.

Werneck de Castro J.P., Fonseca T.L., Ueta C.B., McAninch E.A., Abdalla S., Wittmann G. et al. Differences in hypothalamic type 2 deiodinase ubiquitination explain localized sensitivity to thyroxine. J. Clin. Investig. 2015; 125: 769–81.

Ito M., Miyauchi A., Hisakado M., Yoshioka W., Ide A., Kudo T. et al. Biochemical markers reflecting thyroid function in athyreotic patients on levothyroxine monotherapy. Thyroid. 2017; 27: 484–90.

Hoermann R., Midgley J.E., Larisch R., Dietrich J.W. Is pituitary TSH an adequate measure of thyroid hormone-controlled homeostasis during thyroxine treatment? Eur. J. Endocrinol. 2013; 168: 271–80.

Escobar-Morreale H.F., Obregon M.J., Escobar del Rey F., Morreale de Escobar G. Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. Endocrinology. 1995; 28: 2828–38.

Escobar-Morreale H.F., Escobar del Rey F., Obregon M.J., Morreale de Escobar G. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomised rat. Endocrinology. 1996; 137: 2490–502.

Panicker V., Saravanan P., Vaidya B., Evans J., Hattersley A.T., Frayling T.M., Dayan C.M. Common variation in the DIO2 gene predicts baseline psychological well-being and response to combination thyroxine plus triiodothyronine therapy in hypothyroid patients. J. Clin. Endocrinol. Metab. 2009; 94: 1623–29.

Castagna M.G., Dentice M., Cantara S., Ambrosio R., Maino F., Porcelli T. et al. DIO2 Thr92Ala reduces deiodinase-2 activity and serum-T3 levels in thyroid-deficient patients. J. Clin. Endocrinol. Metab. 2017; 102: 1623–30.

Wouters H.J., van Loon H.C., van der Klauw M.M., Elderson M.F., Slagter S.N., Kobold A.M. et al. No effect of the Thr92Ala polymorphism of deiodinase-2 on thyroid hormone parameters, health-related quality of life, and cognitive functioning in a large population-based cohort study. Thyroid. 2017; 27(2): 147–55.

Appelhof B.C., Peeters R.P., Wiersinga W.M., Visser T.J., Wekking E.M., Huyser J. et al. Polymorphisms in type 2 deiodinase are not associated with well-being, neurocognitive functioning, and preference for combined thyroxine/3,5,3′-triiodothyronine therapy. J. Clin. Endocrinol. Metab. 2005; 90(11): 6296–9.

Gullo D., Latina A., Frasca F., LeMoli R., Pellegritti G., Vigneri R. et al. Levothyroxine monotherapy cannot guarantee euthyroidism in all athyreotic patients. PLoS ONE 6. 2011; e22552.

Medici M., Chaker L., Peeters R.P. A step forward in understanding the relevance of genetic variation in type 2 deiodinase. J. Clin. Endocrinol. Metab. 2017; 102: 1775–8.

Carlé A., Faber J., Steffensen R., Laurberg P., Nygaard B. Hypothyroid patients encoding combined MCT10 and DIO2 gene polymorphisms may prefer L-T3+L-T4 combination treatment – data using a blind, randomized clinical study. Eur. Thyroid J. 2017; 6: 143–51.

Kaminski J., Miasaki F.Y., Paz-Filho G., Graf H., de Carvalho G.A. Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. Arch. Endocrinol. Metab. 2016; 60: 562–72.

Hoermann R., Midgley J.E.M., Larisch R., Dietrich J.W. Lessons from randomised clinical trials for triiodothyronine treatment of hypothyroidism: have they achieved their objectives? J. Thyroid Res. 2018: 1-9.

Kaminski J., Miasaki F.Y., Paz-Filho G., Graf H., de Carvalho G.A. Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. Arch. Endocrinol. Metab. 2016; 60: 562–72.

Hennessey J.V., Espaillat R. Current evidence for the treatment of hypothyroidism with levothyroxine/levotriiodothyronine combination therapy versus levothyroxine monotherapy. Int. J. Clin. Pract. 2018; 72: e13062.

Leese G.P., Soto-Pedre E., Donnelly L.A. Liothyronine use in a 17 year observational population-based study – the TEARS study. Clin. Endocrinol. 2016; 85: 918–25.

Kanji S., Neilipovitz J., Neilipovitz B., Kim J., Haddara W.M.R., Pittman M. et al. Triiodothyronine replacement in critically ill adults with non-thyroidal illness syndrome. Can. J. Anaesth. 2018; 65(10): 1147-53.

Pingitore A., Mastorci F., Piaggi P., Donato Aquaro G., Molinaro S., Ravani M. et al. Usefulness of Triiodothyronine Replacement Therapy in Patients With ST Elevation Myocardial Infarction and Borderline/Reduced Triiodothyronine Levels (from the THIRST Study). Am. J. Cardiol. 2019; 123(6): 905-12.

Ключевые слова